Jacqueline Nicholas

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 103 citations

Relapsing-remitting Multiple Sclerosis, Clinical Neurology, Clinical Trials +8

Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)

Ellen M. Mowry, Robert Bermel, James R. Williams et al. · Frontiers in Neurology · 2020 · 88 citations · Full text

Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database

Aaron Boster, Jacqueline Nicholas, Ning Wu et al. · Neurology and Therapy · 2017 · 78 citations · Full text

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

Stephen L. Hauser, Anne H. Cross, Kevin Winthrop et al. · Multiple Sclerosis Journal · 2022 · 73 citations · Full text

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study

Amit Bar‐Or, Heinz Wiendl, Xavier Montalbán et al. · Multiple Sclerosis Journal · 2021 · 59 citations · Full text